American Heart Journal
Volume 148, Issue 6 , Pages 951-957 , December 2004

Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT)

  • Lawrence Baruch, MD

      Affiliations

    • Bronx VA Medical Center, Bronx, NY, USA
    • Corresponding Author InformationReprint requests: Lawrence Baruch, MD, Bronx VA Medical Center, 130 West Kingsbridge Road, Bronx , NY 10468, USA.
    • ,
  • Robert D. Glazer, MD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    • ,
  • Nora Aknay, BSc

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    • ,
  • Johan Vanhaecke, MD, PhD

      Affiliations

    • U.Z. Gasthuisberg, Leuven, Belgium
    • ,
  • J. Thomas Heywood, MD

      Affiliations

    • Loma Linda University Medical Center, Loma Linda, Calif, USA
    • ,
  • Inder Anand, MD, D Phil, FRCP

      Affiliations

    • VA Medical Center, Minneapolis, Minn, USA
    • ,
  • Henry Krum, MBBS, PhD, FRACP

      Affiliations

    • Monash University Medical School, Alfred Hospital, Melbourne, VIC, Australia
    • ,
  • Allen Hester, PhD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    • ,
  • Jay N. Cohn, MD

      Affiliations

    • University of Minnesota, Minneapolis, Minn, USA

Received 20 February 2004 ,Accepted 4 June 2004.

References 

  1. Ho KK, Anderson KM, Kannel WB, et al.  Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107–115
  2. McDonagh TA, Morrison CE, Lawrence A, et al.  Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997;350:829–833
  3. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121:951–957
  4. Brown AM, Cleland JG. Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J. 1998;19:1063–1069
  5. Cleland JG, Swedberg K, Poole-Wilson PA. Successes and failures of current treatment of heart failure. Lancet. 1998;352(Suppl 1):SI19, SI28
  6. Cleland JG. Heart failure (a medical hydra). Lancet. 1998;352(Suppl 1):SI1, SI2
  7. Parameshwar J, Shackell MM, Richardson A, et al.  Prevalence of heart failure in three general practices in northwest London. Br J Gen Pract. 1992;42:287–289
  8. Cleland JG, Gemmell I, Khand A, et al.  Is the prognosis of heart failure improving?. Eur J Heart Fail. 1999;1:229–241
  9. McMurray J, McDonagh T, Morrison CE, et al.  Trends in hospitalization for heart failure in Scotland 1980–1990. Eur Heart J. 1993;14:1158–1162
  10. Cleland JG, Clark A. Has the survival of the heart failure population changed? Lessons from trials. Am J Cardiol. 1999;83:112D–119D
  11. Hunt SA, Baker DW, Chin MH, et al.  ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult (executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America). Circulation. 2001;104:2996–3007
  12. Cohn JN, Tognoni G, Glazer RD, et al.  Rationale and design of the Valsartan Heart Failure Trial (a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure). J Card Fail. 1999;5:155–160
  13. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675
  14. Latini R, Masson S, Anand I, et al.  Effect of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. Circulation. 2002;106:2454–2458
  15. Cohn JN, Anand IS, Latini R, et al.  Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure (results from Val-HeFT). Circulation. 2003;108:1306–1309
  16. Wong M, Staszewsky L, Latini R, et al.  Valsartan benefits left ventricular structure and function in heart failure (Val-HeFT echocardiographic study). J Am Coll Cardio. 2002;40:970; –5vi
  17. Carson P, Tognoni G, Cohn JN. Effect of valsartan on hospitalization (results from Val-HeFT). J Cardiac Fail. 2003;9:164–171
  18. Havranek EP, Abrams F, Stevens E, et al.  Determinants of mortality in elderly patients with heart failure (the role of angiotensin-converting enzyme inhibitors). Arch Intern Med. 1998;158:2024–2028
  19. Ahmed A, Allman RM, DeLong JF, et al.  Age-related underutilization of angiotensin-converting enzyme inhibitors in older hospitalized heart failure patients. South Med J. 2002;95:703–710
  20. Singh V, Christiana J, Frishman WH. How to use calcium antagonists in hypertension (putting the JNC-VI guidelines into practice. Joint National Committee for the Prevention, Detection, Evaluation and Treatment of High Blood Pressure). Drugs. 1999;58:579–587
  21. de Leeuw PW, Birkenhager WH. The elderly hypertensive; cardiovascular and neurohormonal profile. Cardiovasc Drugs Ther. 2001;15:263–267
  22. Seifarth C, Trenkel S, Schobel H, et al.  Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol. 2002;57:457–465
  23. Jessup M, Brozena S. Heart Failure. N Engl J Med. 2003;348:2007–2018

PII: S0002-8703(04)00393-X

doi: 10.1016/j.ahj.2004.06.001

American Heart Journal
Volume 148, Issue 6 , Pages 951-957 , December 2004

Article Tools

* Image Usage & Resolution